STELARA
Biological
Janssen Research & Development, LLC
Total Payments
$46.4M
Transactions
316,518
Doctors
29,511
Companies
7
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.5M | 44,182 | 11,308 |
| 2023 | $5.7M | 45,337 | 10,361 |
| 2022 | $6.6M | 43,608 | 9,533 |
| 2021 | $3.0M | 38,646 | 7,841 |
| 2020 | $2.4M | 15,198 | 4,639 |
| 2019 | $4.9M | 33,618 | 6,851 |
| 2018 | $7.2M | 34,366 | 7,470 |
| 2017 | $13.1M | 61,563 | 12,360 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $18.2M | 2,278 | 39.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15.2M | 6,279 | 32.8% |
| Food and Beverage | $6.0M | 294,387 | 12.9% |
| Consulting Fee | $3.0M | 1,661 | 6.5% |
| Travel and Lodging | $2.8M | 4,367 | 6.0% |
| Education | $602,753 | 7,326 | 1.3% |
| Space rental or facility fees (teaching hospital only) | $492,800 | 218 | 1.1% |
| Royalty or License | $159,500 | 2 | 0.3% |
Payments by Type
General
$28.3M
314,240 transactions
Research
$18.2M
2,278 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis | Janssen Research & Development, LLC | $5.3M | 0 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease | Janssen Research & Development, LLC | $1.8M | 0 |
| An Open label Randomized Parallel group Study to Assess the Bioequivalence of Ustekinumab Following a Single Subcutaneous Administration by Two Different Injection Devices in Healthy Participants | Janssen Research & Development, LLC | $1.5M | 0 |
| A Phase 3b Randomized Double blind Multi Center Study to Evaluate the Safety and Efficacy of Intravenous Reinduction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease | Janssen Research & Development, LLC | $667,317 | 0 |
| A Phase 3 Study of the Efficacy Safety and Pharmacokinetics of Ustekinumab as Open label Intravenous Induction Treatment Followed by Randomized Double blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants with Moderately to Severely Active Crohn's Disease | Janssen Research & Development, LLC | $472,652 | 0 |
| A Randomized Double-blind Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease | Janssen Research & Development, LLC | $461,913 | 0 |
| A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease | Janssen Research & Development, LLC | $461,806 | 0 |
| NOPRODIBD0002_Sands_Digital Signatures of Drug Response and Disease State Transition in Inflammatory Bowel Disease | Janssen Research & Development, LLC | $450,113 | 0 |
| Digital Signatures of Drug Response and Disease State Transition in Inflammatory Bowel Disease | Janssen Research & Development, LLC | $449,330 | 0 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus | Janssen Research & Development, LLC | $426,395 | 0 |
| CNTO1275JPA3001 | Janssen Research & Development, LLC | $392,423 | 0 |
| Open-label Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Ustekinumab in Pediatric Participants | Janssen Research & Development, LLC | $384,465 | 0 |
| CNTO1275CRD3010 | Janssen Research & Development, LLC | $361,346 | 22 |
| Using clinical records to compare results from a Ustekinumab comparator control arm in a Crohn's Disease Randomized Clinical Trial | Janssen Research & Development, LLC | $344,274 | 0 |
| Phase IV randomized double blind placebo controlled study of the effects of Ustekinumab on vascular inflammation in psoriasis | Janssen Research & Development, LLC | $332,341 | 0 |
| Boston Childrens Hospital therapeutic platforms in IBD | Janssen Research & Development, LLC | $303,004 | 0 |
| An observational retrospective analyses using existing data collected from multiple US IBD centers to evaluate the effectiveness of Ustekinumab for Crohns Disease. | Janssen Scientific Affairs, LLC | $251,353 | 0 |
| Phase IV randomized double blind placebo controlled study of the effects of Ustekinumab on vascular inflamation in psoriasis | Janssen Research & Development, LLC | $224,268 | 0 |
| A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Openlabel Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis | Janssen Research & Development, LLC | $224,073 | 0 |
| An Open Label and Long Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients with Ichthyoses | Janssen Research & Development, LLC | $208,807 | 0 |
Top Doctors Receiving Payments for STELARA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Barbara Matthews | — | Bryn Mawr, PA | $19.5M | 2,570 |
| , MD | Gastroenterology | Louisville, KY | $704,201 | 456 |
| , MD | Gastroenterology | New York, NY | $479,757 | 482 |
| , MD | Gastroenterology | Gainesville, FL | $431,735 | 394 |
| , MS MD PHD | Allergy & Immunology | Williamsville, NY | $412,976 | 295 |
| , MD | Internal Medicine | Orange, CA | $395,914 | 404 |
| , MD | Gastroenterology | San Antonio, TX | $384,461 | 422 |
| , M.D | Internal Medicine | Jackson, MS | $345,367 | 273 |
| , MD PHD | Internal Medicine | Boston, MA | $337,400 | 30 |
| , MD | Gastroenterology | Houston, TX | $321,700 | 638 |
| , MD | Rheumatology | Shreveport, LA | $294,977 | 211 |
| , DO | Gastroenterology | Ft Carson, CO | $292,060 | 188 |
| , M.D | Gastroenterology | Southlake, TX | $259,688 | 313 |
| , MD | Gastroenterology | Morristown, NJ | $241,405 | 184 |
| , APN | Adult Health | Hoffman Estates, IL | $221,495 | 353 |
| , MD | Gastroenterology | Suwanee, GA | $219,282 | 258 |
| , MD, MPH | Gastroenterology | Las Vegas, NV | $219,214 | 248 |
| , M.D | Rheumatology | Midland Park, NJ | $210,992 | 154 |
| , M.D | Rheumatology | Redwood City, CA | $194,727 | 201 |
| , MD | Gastroenterology | Tampa, FL | $187,501 | 139 |
| , MD | Rheumatology | Saint Clair Shores, MI | $182,736 | 168 |
| , MD | Rheumatology | San Antonio, TX | $176,700 | 101 |
| , MD | Gastroenterology | Atlanta, GA | $176,342 | 167 |
| , MD | Gastroenterology | New York, NY | $173,920 | 289 |
| Mark Fleisher | Gastroenterology | Jacksonville, FL | $173,673 | 201 |
Ad
Manufacturing Companies
- Janssen Research & Development, LLC $18.0M
- Janssen Scientific Affairs, LLC $17.2M
- Janssen Biotech, Inc. $10.8M
- Janssen Global Services, LLC $298,120
- Janssen Pharmaceuticals, Inc $77,261
- Johnson & Johnson Health Care Systems Inc. $48,853
- Medical Device Business Services, Inc. $28.84
Product Information
- Type Biological
- Total Payments $46.4M
- Total Doctors 29,511
- Transactions 316,518
About STELARA
STELARA is a biological associated with $46.4M in payments to 29,511 healthcare providers, recorded across 316,518 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Research & Development, LLC.
Payment data is available from 2017 to 2024. In 2024, $3.5M was paid across 44,182 transactions to 11,308 doctors.
The most common payment nature for STELARA is "Unspecified" ($18.2M, 39.1% of total).
STELARA is associated with 20 research studies, including "Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis" ($5.3M).